Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
View Patent ↗Disclosed herein is a method for protecting humans in need of such protection from physical damage caused by ionizing radiation comprising administering to said humans on a defined basis prior to and after exposure to such radiation a plurality of antioxidants at a dosage level directly proportional to the radiation level likely to be encountered.
1. A formulation consisting essentially of:
Vitamin A (palmitate)
5,000 I.U.
Beta-carotene (from natural D. salina)
15 mg
Vitamin D-3 (cholecalciferol)
400 I.U.
Natural soucre Vitamin E
(d-alpha tocopherol)
100 I.U.
(d-alpha tocopheryl acid succinate)
100 I.U.
Buffered Vitamin C (calcium ascorbate)
500 mg
Thiamine mononitrate
4 mg
Riboflavin
5 mg
Niacinamide ascorbate
30 mg
d-calcium pantothenate
10 mg
Pyridoxine hydrochloride
5 mg
Cyanocobalamin
10 μg
Folic Acid (Folacin)
800 μg
D-Biotin
200 μg
Selenium (1-seleno-methionine)
100 μg
Chromium picolinate
50 μg
Zinc glycinate
15 mg
Calcium citrate
250 mg
Magnesium citrate
125 mg
and a booster formulation selected from a group consisting essentially of 1000 mg of vitamin C, 400 international units of d-alpha tocopheryl acid succinate, 200 international units of alpha tocopherol, 500 mg of N-acetyl cysteine, 50 mg of beta-carotene, and 100 mg of alpha lipoic acid, wherein said formulation is designed to reduce the risk in humans exposed to ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, and thyroid cancer.
2. The formulation of claim 1 wherein said dosage is taken prior to anticipated exposure.
3. The formulation of claim 1 wherein said dosage is taken after exposure.
4. The formulation of claim 1 wherein said formulation is taken by user after exposure for a period of at least seven days.
5. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 0.5 mSv or less.
6. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 0.5-5 mSv.
7. The formulation of claim 1 wherein said formulation is designed for a human who receives internal radionuclide exposures.